Best of 5 Bio-Technology Comapnies In India

had to handle five times their turnover in one year, and they
clocked their first 100 Cr plus turnover that year.
However, Vaishali says proudly, “Rather than the turnover,
what was more satisfying was that we could serve the
nation when it was most needed. We are thankful to ICMR-
NIV and our principal client Thermo Fisher Scientific for
trusting in us.”
Discipline, Integrity and Positivity
Recently Nirav Biosolutions celebrated its 10th anniversary
in a new office space. Vaishali feels, "With a humble
beginning from a 330 Sq. ft office to a 3000 sq. ft. it is a
fulfilling journey." Even for IABRD, the new lab is
designed to be GLP compliant; this setup needs to work in
the drug discovery domain offering its services to Pharma
and Biopharma customers looking for discovery service
partners. Also, it will give students the experience of
training in a GLP-compliant lab.
Vaishali reveals, “Our Vision is to be a leading Solution
Provider in the life science industry for the betterment of
the Planet. As per our mission statement, we plan to take
the brand globally.”
With the Government initiative of Start-up and Make in
India, many Biotech startups are coming up. And with its
strengths being Marketing and Sales, Nirav Biosolutions
would like to take these brands to the international market.
"We have already started building capabilities around this
and are associated with many start-ups," says Vaishali.
Ritualistic Continuous Improvement
According to Vaishali, from the business perspective,
COVID-19 has made the world realise the promise that
Biotechnology holds, whether diagnostics or vaccines.
Secondly, it has made the Biotech Industry and
International Regulatory Authorities realise that they were
really moving at a very sluggish pace. They have the
capability of developing health care solutions at a much
faster rate.
The coming years will be for therapeutic antibodies,
vaccines, POC (point of care) solutions, molecular
diagnostics and Biosimilar.
Vaishali states, “A lot of basic research has happened in our
country over a few decades, and there are many aspiring
scientists who are coming up with their innovations in
healthcare with the support of the Government initiative
under BIRAC.” This is definitely going to boost the
industry.
Putting Down the Pandemic
About their pandemic experience and overcoming it,
Vaishali says, “During the pandemic, we had to be on the
front foot as we were the only leading suppliers to ICMR,
NIV, which was the epicentre of all the diagnostics during
the first wave when no kits were available.
As a policy, we provide opportunities to freshers from rural
parts. Post Lockdown announcement, our team had to be
mobilized to their hometown as no PGs were working.”
Most of the activity involved physical involvement in
arranging COVID testing reagents and delivering them to
ICMR-NIV; Nirav Biosolutions had to operate with
logistics support.
“However, teams were kept engaged in online training and
motivational talks from our side. We also kept them updated
about what was happening at the ground level,” reveals
Vaishali.
Value Adding Tech-Knowledge
Vaishali's opinion on biotech companies' need to align their
offerings with technologies like AI and ML, especially
when catering to the ever-evolving healthcare needs, is
cautiously optimistic. She says that having AI and ML in
the Biotech manufacturing process can bring in a lot of
automation and reduce error, thereby improving
productivity.
It is a personal belief that the same should not be applied in
diagnostics and treatment because it can never replace
clinical findings. Also, AI and ML will play a very limiting
role in the Research and Development of new therapies as
biological systems are complex and do not function like a
machine.
However, AI and ML can assist in both healthcare and R&D
to capture data, reproduce it for future reference, and
provide some analytics which can guide Clinicians and
Scientists to take decisions, but it cannot become SOP.
29 | May 2022 | www.insightssuccess.in